Mazdutide
PRIME
Innovent · Phase 4 · Recruiting · Enrollment 60
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| GLP-1/GCG receptor dual agonist plus lifestyle optimization (GG Group) | n/r | n/r | n/r | n/r |
| Lifestyle optimization only (LL group) | n/r | n/r | n/r | n/r |
Not shown
- GLP-1/GCG receptor dual agonist plus lifestyle optimization (GG Group): endpoint not reported
- Lifestyle optimization only (LL group): endpoint not reported